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ABSTRACT 
Background: Hypertensive disorders during pregnancy occur in women with preexisting primary or secondary chronic 
hypertension, and in women who develop new-onset hypertension in the second half of pregnancy. Early detection of 
preeclampsia will help reduce the morbidities and mortalities associated with the disorder. The study aims to evaluate the 
clinical utility of second trimester MAP in the prediction of preeclampsia or gestational hypertension.  Methods: This was 
a prospective cohort study of 200 normotensive, nonproteinuric pregnant women without prior history of gestational 
hypertension. The women were booked patients attending the antenatal clinic at a tertiary care teaching Hospital, Haldia 
and were all in their second trimesters of pregnancy. The outcome measures were systolic blood pressure, diastolic blood 
pressure, and MAP. The end point of the study was the development of preeclampsia or gestational hypertension. The 
diagnosis of preeclampsia was made by the attending obstetrician.  Results: A prospective observational study was carried 
out on 200 pregnant women between 16-26 weeks of gestation during the time period of 1st Jan 2016- 30th Dec 2016 and 
results were analyzed. The maximum number of subjects (51.5%) were in the peak reproductive age group of 26-30 years 
followed by 21.5% and 18% from (21-25 yrs) and 31-35 yrs respectively. The mean age of the study cases was 27.90 
years with a SD of ±7.24. The youngest in the study was 19 years of age and eldest was 42 years of age. The parity 
distribution of the study population was primigravida (39.5%) and 60.5% were multigravida. The development of 
gestational hypertension among the subjects was 11.5%. Rest of the pregnant women were normotensive. The maximum 
number of subjects in the gestational hypertension group was in the age group of 26-30 years (n=23, 34.8%) followed by 21-25 
yrs age group (30.4%) and 31-35 yrs age group (17.4%).  Conclusions: Accurate measurement of blood pressure (BP) is 
crucial to the diagnosis and management of hypertensive disorders in pregnancy  
Key words: Mean arterial blood pressure, pregnancy, gestational hypertension, preeclampsia, systolic blood 
pressure, diastolic blood pressure 
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INTRODUCTION 
 
Hypertension is the most common medical problem 
encountered during pregnancy, complicating up to 10% 
of pregnancies[1].Hypertensive disorders during 
pregnancy are classified into 4 categories, as 
recommended by the National High Blood Pressure  
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 Chronic hypertension 
 Preeclampsia-eclampsia 
 Preeclampsia superimposed on chronic 
hypertension 
 Gestational hypertension (transient hypertension of 
pregnancy or chronic hypertension identified in the 
latter half of pregnancy). This terminology is 
preferred over the older but widely used term 
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"pregnancy-induced hypertension" (PIH) because 
it is more precise. 
Pregnancies complicated by pre-eclampsia, chronic 
hypertension, or both, are at significantly increased risk 
of adverse outcomes. For most women, the assessment 
of blood pressure and urinalysis form the mainstay of 
routine antenatal care[3]. Pre-eclampsia is the most 
severe form of hypertensive disorder of pregnancy and 
is associated with maternal and fetal 
mortality, intrauterine growth restriction, and preterm 
birth[4,5].  It is defined as de novo high blood pressure 
occurring after 20 weeks’ gestation in conjunction with 
proteinuria[4-6]. The pathophysiology of preeclampsia 
is heterogeneous, complex, and poorly understood 
involving both maternal and placental factors[7]. 
Abnormalities in the development of placental 
vasculature is considered to be a primary cause of the 
placental hypoxia and ischemia, which then leads to 
release of numerous bioactive factors into the maternal 
circulation causing widespread endothelial dysfunction 
 and culminating in hypertension, proteinuria and other 
manifestations of the disease affecting the liver, renal, 
hematological, and central nervous systems[8,9]. 
Hypertensive disorders of pregnancy (HDP) 
remain among the most significant and intriguing 
unsolved problems in obstetrics. In India, the 
prevalence of HDP was 7.8% with pre-eclampsia in 
5.4% of the study population[10].Mehta B et al study 
indicated that the prevalence of hypertension in 
pregnancy was significantly higher in pregnant women 
with gestational period ≤20 weeks (10.0%) than 
women with gestational period >20 weeks 
(5.3%)[11].However in various hospital-based studies, 
frequency of preeclampsia and eclampsia was found to 
be higher which manifests after 20 weeks of 
gestation[12-14].  Early detection of preeclampsia 
would allow for appropriate monitoring and 
management to forestall the development of 
complications. The objective of this screening study is 
to investigate the potential value of and compare MAP, 
systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) 4 weeks apart between 16 to 26 weeks 
of gestation in the prediction of PE. 
Materials & methods 
This was a prospective cohort study of 200 
normotensive, nonproteinuric pregnant women without 
prior history of gestational hypertension.  
Inclusion Criteria 
1. First visit at or before 20 weeks of pregnancy. 
2. Singleton pregnancy. 
Exclusion Criteria 
1. Patients with other disorders complicating 
pregnancy such as essential hypertension, heart 
disease, renal disease, diabetes, hydramnios, 
twins, Rh negative pregnancy were excluded. 
2. Gross congenital anomaly in the foetus. 
Blood pressure was measured for each patient at every 
visit by auscultatory method. Blood pressure of each 
patient was recorded at each visit by the same 
instrument. The recording was taken after the patient 
was seated for at least 10 minutes to remove the effect 
of excitement. At least two readings, 4 weeks apart 
between 16 to 26 weeks of gestation was taken. Mean 
arterial pressure was calculated.  Mean arterial blood 
pressure in second trimester (MAP) was taken as the 
average of two readings. 
The women were booked patients attending 
the antenatal clinic at a tertiary care teaching hospital 
and were all in their second trimesters of pregnancy at 
recruitment. The outcome measures were systolic 
blood pressure, diastolic blood pressure, and estimation 
of the MAP. The end point of the study was the 
development of preeclampsia. Pregnant women were 
diagnosed with preeclampsia if they developed 
hypertension with systolic blood pressure ≥ 140 mmHg 
and/or diastolic blood pressure ≥ 90 mmHg and ≥ 2+ of 
proteinuria[15]. Late-onset preeclampsia was defined 
as the onset of clinical disease after 34 weeks gestation 
and early-onset preeclampsia as starting before 34 
weeks gestation. The blood pressure was determined 
using the Accoson's Mercury Sphygmomanometer 
(cuff size 15 × 43 cm). The subjects were seated and 
rested for 5 min before measurement. The systolic 
blood pressure was taken at the first korotkoff sound 
and diastolic at the fifth korotkoff 
sound[15].Preeclampsia was defined as the onset, after 
20 weeks gestation of proteinuria ( ≥300 mg/24 h or 
≥100 mg/L, equivalent to ≥ 2+ on dipstix urinaysis) on 
at least two random urine samples at least 4 to 6 h apart 
but not more than 7 days apart, and systolic blood 
pressure ≥140 mmHg or a diastolic blood pressure ≥ 90 
mmHg measured using an appropriate sized cuff 
repeatable at least 4–6 hours apart but not more than 7 
days apart and a remission of these symptoms by 6 
weeks postpartum[15].Approval for the study was 
obtained from the institutional ethics committee and 
consenting subjects signed an informed consent form. 
At recruitment, initial blood pressure measurements 
were recorded and the MAP calculated by dividing the 
sum of the systolic and twice the diastolic blood 
pressure by three[16].  
Results 
A prospective observational study was carried 
out on 200 pregnant women between 16-26 weeks of 
gestation during the time period of 1st Jan 2016- 30th 
Dec 2016 and results were analyzed. The maximum 
number of subjects (51.5%) were in the peak 
reproductive age group of 26-30 years followed by 
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21.5% and 18% from (21-25 yrs) and 31-35 yrs 
respectively. The mean age of the study cases was 
27.90 years with a SD of ±7.24. The youngest in the 
study was 19 years of age and eldest was 42 years of 
age. The parity distribution of the study population 
were primigravida (39.5%) and 60.5% were 
multigravida [Table 1]. 
 
Table 1: Demographic and clinical characteristics of study participants (n=200)  
Age Groups Frequency % 
<=20 yrs 7 3.5% 
21 - 25 yrs 43 21.5% 
26 - 30 yrs 103 51.5% 
31 - 35 yrs 36 18% 
36 - 40 yrs 9 4.5% 
≥ 40 yrs 02 1% 
Primi 79 39.5% 
Multi 121 60.5% 
Total 200 100% 
 
Table 2: Development of gestational hypertension among study participants  
GHTN Frequency % 
No 177 88.5% 
Yes 23 11.5% 
Total 200 100% 
Table 2 shows the development of gestational hypertension among the subjects was 11.5%. Rest of the pregnant 
women was normotensive. 
 
Table 3: Age distribution and development of gestational hypertension (n=200) 
Age Groups 
No GHTN GHTN 
P Value 
Frequency % Frequency % 
<=20 yrs 7 3.95% 0 0.0% - 
21 - 25 yrs 36 20.34% 7 30.4% P = 0.5611 
26 - 30 yrs 95 53.67% 8 34.8% P = 0.3072 
31 - 35 yrs 32 18.1% 4 17.4% P = 0.9730 
36 - 40 yrs 06 3.4% 3 13.04% P = 0.6050 
≥ 40 yrs 01 0.06% 1 4.34% P = 0.8840 
Total 177 100% 23 100% - 
Table 3 shows the development of gestational hypertension in various age groups. The maximum number of 
subjects in the gestational hypertension group was in the age group of 26-30 years (n=23, 34.8%) followed by 21-25 yrs 
age group (30.4%) and 31-35 yrs age group (17.4%).  
Table 4: Distribution of subjects according to mean arterial pressure among pregnant women [n=200] 
MAP  Frequency % 
70 - 75 10 5% 
76 - 80 38 19% 
81 - 85 69 34.5% 
86 - 90 46 23% 
91 - 95 22 11% 
96 - 100 13 6.5% 
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>100 2 1% 
Total 200 100% 
Table 4 shows the distribution of subjects according to various ranges of MAP. The maximum number of subjects (n=69, 
34.5%) fall in the MAP range of (80-85) followed by 23% of (86-90) whereas the minimum number of subjects (n=2, 1%) 
fall in the MAP range of >100. 
Table 5: Development of gestational hypertension at various ranges of mean arterial pressures [n=200] 
MAP Total Patients GHTN % 
70 - 75 10 0 0% 
76 - 80 38 0 0% 
81 - 85 69 1 1.45% 
86 - 90 46 4 8.7% 
91 - 95 22 6 13.64% 
96 - 100 13 10 76.92% 
>100 2 2 100% 
Total 200 23 11.5% 
 
Table 5 shows the development of gestational 
hypertension at various MAP ranges. None of the 
patients (0%) who had MAP in the range of 70-75 and 
76-80 developed gestational hypertension, whereas all 
the patients (100%) who had MAP > 100 developed 
gestational hypertension. The second highest incidence 
of gestational hypertension was in the MAP range of 
96-100 (76.92%). It was seen that as the MAP 
increases, incidence of gestational hypertension 
increases. 
DISCUSSION 
The strengths of this screening study for PE 
are, firstly, the prospective examination of a large 
population of pregnant women attending for routine 
care in a well-defined gestational age range which is 
widely used for the assessment of fetal growth and 
well-being, secondly, the use of a well-defined 
methodology and appropriately trained doctors to 
measure blood pressure and thirdly, the application of a 
statistical approach that is widely accepted in screening 
for aneuploidies and pregnancy complications to 
examine the performance of screening and calculate 
patient-specific risks[17].  
The definition of hypertension in pregnancy 
was not uniform for a long time[18,19]; it used to be 
defined as an elevation in blood pressure during the 
second trimester from a baseline reading in the first 
trimester or from pre-pregnancy levels. However, a 
definition based on absolute blood pressure values 
(systolic blood pressure ≥140 mmHg or diastolic blood 
pressure ≥90 mmHg) is now preferred. Hypertension in 
pregnancy is not a single entity but comprises (i) pre-
existing hypertension; (ii) gestational hypertension 
with its subunit of (iii) pre-eclampsia; (iv) pre-existing 
hypertension with superimposed gestational 
hypertension with proteinuria; and (v) antenatally 
unclassifiable hypertension[20]. 
 Antenatal Care guidance recommends BP 
measurement at every antenatal visit and outlines the 
steps involved in BP measurement using the 
auscultatory technique. This includes use of the 
correct-sized cuff, initial inflation of the cuff 20–30 
mmHg above the palpable systolic BP, deflation at a 
rate of 2 mmHg per second, recording BP to the nearest 
2 mmHg and use of Korotkoff phase V to indicate 
diastolic BP[21].  
Hypertensive pregnancy disorders complicate 
10% of all pregnancies and cover a spectrum of 
conditions, namely preeclampsia, eclampsia, and 
chronic and gestational hypertension. Preeclampsia is a 
pregnancy-specific disorder clinically characterized by 
hypertension and proteinuria that occurs after 20 weeks 
of gestation. It remains a leading cause of both fetal 
and maternal morbidity and mortality worldwide[22].  
Although the exact pathophysiologic mechanism is not 
clearly understood, preeclampsia is primarily a disorder 
of placental dysfunction leading to a syndrome of 
endothelial dysfunction with associated vasospasm. In 
most cases, pathology evaluation demonstrates 
evidence of placental insufficiency with associated 
abnormalities such as diffuse placental thrombosis, an 
inflammatory placental decidual vasculopathy, and/or 
abnormal trophoblastic invasion of the 
endometrium. The hypertension occurring in 
preeclampsia is due primarily to vasospasm, with 
arterial constriction and relatively reduced 
intravascular volume compared with that of a normal 
pregnancy[23].  
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 Blood pressure measurement is a screening 
test that is used in antenatal care to detect or predict 
hypertensive disease.6 Prediction of women at risk for 
developing gestational hypertension or pre-eclampsia is 
crucial to allocation of monitoring resources and, 
possibly, use of preventive treatment. Poon and co-
workers used the combination of maternal medical 
history and mean arterial pressure at 11+0 to 13+6 weeks 
gestation to predict pre-eclampsia and gestational 
hypertension and found that, for a 10% false-positive 
rate, 60% of those who will develop pre-eclampsia, and 
40% of those who will develop gestational 
hypertension, can be identified[24]. 
In a meta-analysis involving 34 studies and 
60599 women, mean arterial pressure was a better 
predictor of pre-eclampsia than systolic blood pressure, 
diastolic blood pressure, or an increase in blood 
pressure when blood pressure was measured in the first 
or second trimester of pregnancy. Diastolic blood 
pressure and mean arterial pressure were more strongly 
associated with the risks of pregnancy-induced 
hypertension and pre-eclampsia as compared with 
systolic blood pressure[25].Age and parity are two of 
the identified maternal risk factors for the development 
of GHTN. Extremes of age (age below 20 years and 
above 35 years) are known to be associated with higher 
incidence of GHTN. Like the overall incidence of 
GHTN, incidence among various age groups and parity 
varies from place to place[26]. In Karachi, found an 
incidence of 9% among older women and 27% among 
primigravidae. However, reported an incidence of 
hypertensive disorders of pregnancy of 41.3% among 
18-22 years old patients in their own study.11 53.8% of 
these study participants were primigravidae[27]. In 
normal pregnancy, BP initially decreases until 18 to 20 
weeks' gestation and then rises until delivery [28-30], 
and studies have indicated that higher BP pre-
pregnancy and in the first trimester are associated with 
increased risk of developing gestational hypertension 
and preeclampsia[25,31,32].Study by Heta G. Vyas et 
al revealed total 121 numbers of women were 
diagnosed with pregnancy induced hypertension in 
their study. Out of that 53.72% were in the young age 
group and 67.77% were primigravida[33]. 
Hypertensive pregnant women having twin gestation 
are more prone to development of PIH (OR=12.55). 
Pregnant women who had undergone treatment of 
infertility (OR=2.11) and who had history of missed 
abortion (OR=5.54) are more prone to develop 
hypertension. These are novel factors associated with 
PIH. The antenatal care trial research of the World 
Health Organization conducted in some countries of 
South America and Asia showed that the incidence of 
PE was 2.2% and that of gestational hypertension was 
7.0% among pregnant women, including those with 
chronic complications[34]. The Haruka Muto et al 
study demonstrated that the incidence rates of PE and 
GH were 2.6% and 5.8%, respectively[35]. This might 
be because women with chronic disease, who were 
regarded as high risk for hypertensive disorders, were 
excluded in our population. Among the nulliparous 
women, the incidence of PE was 4.1%, which was 
similar to the incidence of 5.3% in a prospective 
observational study of only nulliparous women without 
any chronic complications.36 Among the multiparous 
women, Baschat et al showed an incidence of PE of 
3.1%. This higher incidence could also be explained by 
the different study participants, including any women 
with complications[37]. 
Conclusion 
Measurements of blood pressure recorded 
during the second half of pregnancy, used in 
conjunction with blood pressure early in pregnancy and 
other maternal risk factors, can improve the 
identification of women who are at risk of developing 
pre-eclampsia later in pregnancy and could be used to 
differentiate women who require more intensive 
monitoring from those who are likely to have a normal 
pregnancy. Hypertensive disorders in pregnancy may 
cause maternal and fetal morbidity, and they remain a 
leading source of maternal mortality. 
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